Boston - AG Mednet and the board-certified, fellowship-trained radiologists at Imaging Endpoints believe strongly that every clinical trial data point counts, from pre-clinical through FDA submission. To support its guarantee of accuracy, compliance, real-time reads and sponsor confidence, Imaging Endpoints is utilizing AG Mednet's Submission Quality and Compliance software for oncology, neurology, musculoskeletal and cardiovascular clinical trials.

According to industry research, more than half of all image-related clinical trial query stoppages result from preventable human errors that can delay a trial for up to seven weeks. AG Mednet's Submission Quality and Compliance software immediately detects errors that result in query stoppages and gives core labs a system to verify information, automatically update support systems including EDC (electronic data capture), and dramatically reduce the amount of queries returned for correction or re-scanning.

In clinical trials conducted using AG Mednet technology, sponsors experience a more than 75 percent query reduction rate, resulting in significant cost savings and faster decision times.
"Imaging Endpoints is operated and owned by radiologists and researchers committed to connecting imaging to the cure through novel technology advances," said Imaging Endpoints CEO and President, Doug Dean Burkett, PhD. "Our partnership with AG Mednet helps us automate the quality and submission process to avoid the costly delays and human errors that plague traditional approaches to transferring and submitting clinical trial data. This also assists us in providing economical real-time eligibility and response reads to sponsors conducting clinical trials globally."

Imaging Endpoints provides comprehensive imaging core lab services through the imaging trial process: pre-study, study and post-study. Extensive expertise in imaging allows Imaging Endpoints to perform qualitative and quantitative assessments of both anatomic and physiologic/metabolic imaging modalities in order to better probe the effectiveness of new therapeutics.

"AG Mednet and Imaging Endpoints share a vision for the clinical trial industry. We believe every imaging endpoint counts. Every piece of information - and its accuracy - is vital to the eventual success or failure of a clinical trial," said Abraham Gutman, president and CEO of AG Mednet. "We expect to learn a lot from one another and push the boundaries of clinical trial imaging technology to accomplish new advances in therapies that have monumental impact for patients and pharmaceutical sponsors."

More HCB News